Life Biosciences Treats First Patient with Cell-Rejuvenating Gene Therapy for Glaucoma

Life Biosciences has treated the first patient with ER-100, an experimental gene therapy designed to rejuvenate aged cells in the eye. The therapy, given to a patient with glaucoma, delivers three distinct genetic edits to regenerate retinal ganglion cells in the optic nerve, which do not normally regenerate in adults and can lead to blindness when damaged.

The treatment is based on cellular reprogramming, a concept demonstrated by Japanese researcher Shinya Yamanaka in 2007, who showed that certain proteins can reset adult cells to a stem cell-like state. ER-100 uses the "OSK" factors (OCT4, SOX2, and KLF4), three of the original four Yamanaka factors, to partially reverse age-associated epigenetic changes. The genes are delivered via a virus commonly used in gene therapy and are designed to switch on only when the participant takes the antibiotic doxycycline, giving clinicians the ability to turn the mechanism off if needed.

The Phase 1 trial, approved by the U.S. Food and Drug Administration, includes up to 18 participants: the first 12 with open-angle glaucoma and six with non-arteritic anterior ischemic optic neuropathy (NAION), a condition that causes sudden vision loss. Participants will be monitored for at least five years, with the primary goal of assessing safety rather than effectiveness.

Animal studies in several labs have suggested that partially reprogramming cell tissue can be done safely, though fears remain that the therapy could tip some cells into a cancerous state. Since 2020, researchers reported that activating the three genes caused regeneration of neurons in the optic nerve in mice and reversed vision loss in elderly specimens or those affected by glaucoma. The technology was transferred to Life Biosciences, which subsequently conducted preclinical tests in rodents and primates that revealed no serious adverse effects.

The company's CEO called the moment "a potential transformation not just for the company and not just for the field of aging biology, but, without exaggeration, for the whole of medicine," adding that the therapy aims to restore tissue function and reverse disease at a fundamental level. A co-founder and Harvard geneticist described the trial as "the first opportunity to test whether restoring this information can improve human diseases." Researchers caution that success does not necessarily prove cellular immortality, but Life Biosciences is also experimenting with animal models of liver disease.

Translating the Yamanaka factors into a medicine requires targeted delivery systems, precision control of gene expression, and manufacturing protocols with appropriate potency, release, and quality controls. The durable commercial value of such therapies will depend on the engineering solutions that make the biology clinically usable, including the delivery system, expression controls, manufacturing process, treatment protocol, and clinical validation.